Compile Data Set for Download or QSAR
Report error Found 23 Enz. Inhib. hit(s) with all data for entry = 2226
LigandPNGBDBM357792(US10214533, Compound 2 | (4-chlorophenyl)(3-(3- me...)
Affinity DataIC50: 3.50E+4nMAssay Description:The determination of plasma protein binding (PPB) of a compound is enabled by equilibrium dialysis, an accepted and standard method for reliable esti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

LigandPNGBDBM50112183(CHEMBL3608684 | US10214533, Compound 1 | US9969738...)
Affinity DataIC50: 5.00E+4nMAssay Description:The determination of plasma protein binding (PPB) of a compound is enabled by equilibrium dialysis, an accepted and standard method for reliable esti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM357793(US10214533, Compound 3 | (4-chloro-3- fluorophenyl...)
Affinity DataKi:  93nMAssay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM357792(US10214533, Compound 2 | (4-chlorophenyl)(3-(3- me...)
Affinity DataKi:  99nMAssay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM357794(US10214533, Compound 4 | (3-chloro-4- fluorophenyl...)
Affinity DataKi:  130nMAssay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM50112183(CHEMBL3608684 | US10214533, Compound 1 | US9969738...)
Affinity DataKi:  140nMAssay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM357795(US10214533, Compound 5 | (3,4-difluorophenyl)(3-(3...)
Affinity DataKi:  170nMAssay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM357796(US10214533, Compound 6 | (3-(3-methyl-1,2,4- thiad...)
Affinity DataKi:  170nMAssay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM357797(US10214533, Compound 7 | (3-(3-methyl-1,2,4- thiad...)
Affinity DataKi:  240nMAssay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetSubstance-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM357794(US10214533, Compound 4 | (3-chloro-4- fluorophenyl...)
Affinity DataKi: >3.00E+4nMAssay Description:The affinity of compounds of the invention for the NK-2 receptor was evaluated in CHO recombinant cells which express the human NK-2 receptor. Membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetSubstance-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM357797(US10214533, Compound 7 | (3-(3-methyl-1,2,4- thiad...)
Affinity DataKi: >3.00E+4nMAssay Description:The affinity of compounds of the invention for the NK-2 receptor was evaluated in CHO recombinant cells which express the human NK-2 receptor. Membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetSubstance-P receptor(Human)
Ogeda

US Patent
LigandPNGBDBM357797(US10214533, Compound 7 | (3-(3-methyl-1,2,4- thiad...)
Affinity DataKi: >3.00E+4nMAssay Description:The affinity of compounds of the invention for the NK-1 receptor was evaluated in CHO recombinant cells which express the human NK-1 receptor. Membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetSubstance-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM357796(US10214533, Compound 6 | (3-(3-methyl-1,2,4- thiad...)
Affinity DataKi: >3.00E+4nMAssay Description:The affinity of compounds of the invention for the NK-2 receptor was evaluated in CHO recombinant cells which express the human NK-2 receptor. Membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetSubstance-P receptor(Human)
Ogeda

US Patent
LigandPNGBDBM357796(US10214533, Compound 6 | (3-(3-methyl-1,2,4- thiad...)
Affinity DataKi: >3.00E+4nMAssay Description:The affinity of compounds of the invention for the NK-1 receptor was evaluated in CHO recombinant cells which express the human NK-1 receptor. Membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetSubstance-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM357795(US10214533, Compound 5 | (3,4-difluorophenyl)(3-(3...)
Affinity DataKi: >3.00E+4nMAssay Description:The affinity of compounds of the invention for the NK-2 receptor was evaluated in CHO recombinant cells which express the human NK-2 receptor. Membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetSubstance-P receptor(Human)
Ogeda

US Patent
LigandPNGBDBM357795(US10214533, Compound 5 | (3,4-difluorophenyl)(3-(3...)
Affinity DataKi: >3.00E+4nMAssay Description:The affinity of compounds of the invention for the NK-1 receptor was evaluated in CHO recombinant cells which express the human NK-1 receptor. Membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetSubstance-P receptor(Human)
Ogeda

US Patent
LigandPNGBDBM357794(US10214533, Compound 4 | (3-chloro-4- fluorophenyl...)
Affinity DataKi: >3.00E+4nMAssay Description:The affinity of compounds of the invention for the NK-1 receptor was evaluated in CHO recombinant cells which express the human NK-1 receptor. Membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetSubstance-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM357793(US10214533, Compound 3 | (4-chloro-3- fluorophenyl...)
Affinity DataKi: >3.00E+4nMAssay Description:The affinity of compounds of the invention for the NK-2 receptor was evaluated in CHO recombinant cells which express the human NK-2 receptor. Membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetSubstance-P receptor(Human)
Ogeda

US Patent
LigandPNGBDBM357793(US10214533, Compound 3 | (4-chloro-3- fluorophenyl...)
Affinity DataKi: >3.00E+4nMAssay Description:The affinity of compounds of the invention for the NK-1 receptor was evaluated in CHO recombinant cells which express the human NK-1 receptor. Membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetSubstance-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM357792(US10214533, Compound 2 | (4-chlorophenyl)(3-(3- me...)
Affinity DataKi: >3.00E+4nMAssay Description:The affinity of compounds of the invention for the NK-2 receptor was evaluated in CHO recombinant cells which express the human NK-2 receptor. Membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetSubstance-P receptor(Human)
Ogeda

US Patent
LigandPNGBDBM357792(US10214533, Compound 2 | (4-chlorophenyl)(3-(3- me...)
Affinity DataKi: >3.00E+4nMAssay Description:The affinity of compounds of the invention for the NK-1 receptor was evaluated in CHO recombinant cells which express the human NK-1 receptor. Membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetSubstance-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM50112183(CHEMBL3608684 | US10214533, Compound 1 | US9969738...)
Affinity DataKi: >3.00E+4nMAssay Description:The affinity of compounds of the invention for the NK-2 receptor was evaluated in CHO recombinant cells which express the human NK-2 receptor. Membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetSubstance-P receptor(Human)
Ogeda

US Patent
LigandPNGBDBM50112183(CHEMBL3608684 | US10214533, Compound 1 | US9969738...)
Affinity DataKi: >3.00E+4nMAssay Description:The affinity of compounds of the invention for the NK-1 receptor was evaluated in CHO recombinant cells which express the human NK-1 receptor. Membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent